Age Related Macular Degeneration - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 537
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AB7CC0F0839EN
Leaflet:

Download PDF Leaflet

Age Related Macular Degeneration - Pipeline Review, H2 2017
Age Related Macular Degeneration - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2017, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 27, 18, 4, 135, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 16 and 2 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Age Related Macular Degeneration - Overview
Age Related Macular Degeneration - Therapeutics Development
Age Related Macular Degeneration - Therapeutics Assessment
Age Related Macular Degeneration - Companies Involved in Therapeutics Development
Age Related Macular Degeneration - Drug Profiles
Age Related Macular Degeneration - Dormant Projects
Age Related Macular Degeneration - Discontinued Products
Age Related Macular Degeneration - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Age Related Macular Degeneration, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Abzena Plc, H2 2017
Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Aciont Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2017
Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Alimera Sciences Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Allergan Plc, H2 2017
Age Related Macular Degeneration - Pipeline by Allgenesis Biotherapeutics Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H2 2017
Age Related Macular Degeneration - Pipeline by Alteogen Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Amarna Therapeutics BV, H2 2017
Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Apexigen Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corp, H2 2017
Age Related Macular Degeneration - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Benitec Biopharma Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by BioMAS Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Biophytis SAS, H2 2017
Age Related Macular Degeneration - Pipeline by Caladrius Biosciences Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Catalyst Biosciences Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Cell Medica Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Charlesson LLC, H2 2017
Age Related Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Age Related Macular Degeneration - Pipeline by CJ HealthCare Corp, H2 2017
Age Related Macular Degeneration - Pipeline by Clanotech AB, H2 2017
Age Related Macular Degeneration - Pipeline by Coherus BioSciences Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Co, H2 2017
Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS, H2 2017
Age Related Macular Degeneration - Pipeline by Enzene Biosciences Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Exonate Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Eyevensys SAS, H2 2017
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by FirstString Research Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Formycon AG, H2 2017
Age Related Macular Degeneration - Pipeline by Gene Techno Science Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Genentech Inc, H2 2017
Age Related Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2017
Age Related Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2017
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Icon Bioscience Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Iconic Therapeutics Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Inception Sciences Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Innovent Biologics Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H2 2017

LIST OF FIGURES

Number of Products under Development for Age Related Macular Degeneration, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3SBio Inc
Abzena Plc
Achillion Pharmaceuticals Inc
Aciont Inc
Acucela Inc
AdAlta Ltd
Adverum Biotechnologies Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Alimera Sciences Inc
Alkeus Pharmaceuticals Inc
Allergan Plc
Allgenesis Biotherapeutics Inc
Allinky Biopharma
Alteogen Inc
Amarna Therapeutics BV
Apellis Pharmaceuticals Inc
Apexigen Inc
Applied Genetic Technologies Corp
Ascentage Pharma Group Corp Ltd
Astellas Pharma Inc
Benitec Biopharma Ltd
Biokine Therapeutics Ltd
BioMAS Ltd
Biomics Biotechnologies Co Ltd
Biophytis SAS
Caladrius Biosciences Inc
Catalyst Biosciences Inc
Cell Cure Neurosciences Ltd
Cell Medica Ltd
Charlesson LLC
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Clanotech AB
Coherus BioSciences Inc
Colby Pharmaceutical Co
Crinetics Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Diffusion Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Eleven Biotherapeutics Inc
Elsalys Biotech SAS
Enzene Biosciences Ltd
Exonate Ltd
EyeGate Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
FirstString Research Inc
Foamix Pharmaceuticals Ltd
Formycon AG
Gene Techno Science Co Ltd
Genentech Inc
GenSight Biologics SA
Graybug Vision Inc
HanAll Biopharma Co Ltd
Huabo Biopharm Co Ltd
Icon Bioscience Inc
Iconic Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Inception Sciences Inc
Innovent Biologics Inc
Intellect Neurosciences Inc
Ionis Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
Just Biotherapeutics Inc
Kala Pharmaceuticals Inc
Kodiak Sciences Inc
Lead Discovery Center GmbH
LeadArtis SL
Lee's Pharmaceutical Holdings Ltd
Lupin Ltd
M's Science Corp
Mabion SA
MacuCLEAR Inc
Mitotech SA
Mitsubishi Tanabe Pharma Corp
Mor Research Application Ltd
Navya Biologicals Pvt Ltd
Neovacs SA
Novartis AG
NovelMed Therapeutics Inc
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Ophthotech Corp
Oxford BioMedica Plc
Oxular Ltd
PanOptica Inc
Paras Biopharmaceuticals Finland Oy
Pfenex Inc
Pfizer Inc
PlantForm Corp
Promedior Inc
pSivida Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Ribomic Inc
RXi Pharmaceuticals Corp
SanBio Inc
SciFluor Life Sciences LLC
Senju Pharmaceutical Co Ltd
Stealth BioTherapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
TRACON Pharmaceuticals Inc
Tyrogenex Inc
Wellstat Ophthalmics Corp
Xbrane Biopharma AB
Skip to top


Ask Your Question

Age Related Macular Degeneration - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: